Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ServiceNow Inc (NOW) vs Revvity Inc (RVTY) Price & Performance

ServiceNow IncTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

ServiceNow Inc vs Revvity Inc — how do they compare? ServiceNow Inc trades at $140.1 (market cap $144.48B), while Revvity Inc trades at $155.03 (market cap $16.98B). The key difference: ServiceNow Inc is far larger — about 8.5× Revvity Inc's market cap, and Revvity Inc pays a 0.18% dividend while ServiceNow Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ServiceNow Inc for 54 Days and Revvity Inc for 12 Days on average.

NOWRVTY
Market Cap
$144.48B$16.98B
Volume
11,801,6991,456,900
Sector
TechnologyHealth
52-Week High
$189.26$157.36
52-Week Low
$83.00$82.26
Typical Hold Time
54 Days12 Days
Enterprise Value
$148.27B$19.30B
Dividend Yield
—0.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ServiceNow Inc

ServiceNow (NOW) trades at $137.87, down slightly by 0.07% on the day. The stock shows strong fundamental momentum with revenue growing from $7.2B in 2022 to $13.3B in 2025 and consistent earnings beats in recent quarters. Technical indicators are bullish with the price above key moving averages, while analyst sentiment remains overwhelmingly positive with 87% buy ratings and a $146.04 consensus target. The company's AI business has surpassed $1 billion in annual contract value, driving investor optimism.

ServiceNow presents a compelling growth story with robust AI adoption and expanding enterprise workflow solutions. The primary investment opportunity lies in the company's leadership position in enterprise AI and strong subscription revenue growth. Key risks include premium valuation multiples (P/E of 87.34), increasing competition in cloud software, and potential margin pressure as AI investments scale. The stock offers upside to analyst targets but requires monitoring of execution against ambitious growth projections.

Revvity Inc

Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.

The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NOW
43% Buy57% Sell
Avg holding period · 54 Days
RVTY

No sentiment data available yet.

Top news

Latest headlines on both assets

About ServiceNow Inc

ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).

Read more on NOW →

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY →